DSKYF (Daiichinkyo Co) EBIT: $1,816 Mil (TTM As of Mar. 2026)


DSKYF Daiichi Sankyo Co Ltd DSKYF
73 GF Score
Price $14.76
GF Value $37.40
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Daiichinkyo Co EBIT?

Daiichinkyo Co DSKYF -4.91% 73 EBIT is $1,816 Mil as of Mar. 2026. GuruFocus rates DSKYF with a GF Score™ of 73/100 and a GF Value™ of $37.40 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Daiichinkyo Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $1,816 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Daiichinkyo Co's annualized ROC % for the quarter that ended in Mar. 2026 was 0.00%. Daiichinkyo Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -0.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Daiichinkyo Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.14%.


Daiichinkyo Co  (OTCPK:DSKYF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Daiichinkyo Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-118.148 * ( 1 - 100% )/( (16005.868 + 17429.045)/ 2 )
=-0/16717.4565
=0.00 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=24512.144 - 4131.899 - ( 4374.377 - max(0, 4993.452 - 13438.252+4374.377))
=16005.868

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=25241.504 - 4317.793 - ( 3494.666 - max(0, 5577.312 - 13501.844+3494.666))
=17429.045

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Daiichinkyo Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-74.364/( ( (3707.244 + max(4073.008, 0)) + (3759.471 + max(4432.412, 0)) )/ 2 )
=-74.364/( ( 7780.252 + 8191.883 )/ 2 )
=-74.364/7986.0675
=-0.93 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4463.656 + 4176.692 + 423.527) - (4131.899 + 0 + 858.968)
=4073.008

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4670.61 + 4363.286 + 973.282) - (4317.793 + 0 + 1256.973)
=4432.412

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Daiichinkyo Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1815.835/25415.246
=7.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co EBIT Related Terms


Daiichinkyo Co EBIT Historical Data

* Premium members only.

The historical data trend for Daiichinkyo Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co EBIT Chart

Daiichinkyo Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 668.50 1,012.49 1,623.70 2,465.39 1,710.45

Daiichinkyo Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 588.42 739.61 396.37 698.45 -18.59

DSKYF vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's EV-to-EBIT falls into.


DSKYF
73GF Score
Daiichi Sankyo Co Ltd DSKYF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daiichinkyo Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,816 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $1,816 Mil mean?
Daiichinkyo Co (DSKYF) has a EBIT of $1,816 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Daiichinkyo Co.
Is Daiichinkyo Co's EBIT too high?
Daiichinkyo Co's current EBIT is $1,816 Mil. Overall, Daiichinkyo Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's EBIT compare to LLY and JNJ?
Daiichinkyo Co's EBIT of $1,816 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Daiichinkyo Co. Daiichinkyo Co's current EBIT is $1,816 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $37.40, compared to a current price of $14.76 — trading 60.5% below its estimated fair value. The current EBIT is $1,816 Mil. Daiichinkyo Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current EBIT is $1,816 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daiichinkyo Co (DSKYF) Overvalued in 2026?

Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued. The current stock price of $14.76 is trading 60.5% below its estimated GF Value™ of $37.40. GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.

Key valuation signals for DSKYF:

  • EBIT: $1,816 Mil
  • GF Value™: $37.40 vs. price of $14.76 (60.5% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Daiichinkyo Co Business Description

Address 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score

Get the complete analysis for DSKYF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.76
Price
$37.40
GF Value